Congenital neutropenia: A case study

D. Daghistani, Joaquin J Jimenez, S. R. Toledano, R. E. Cirocco, Adel A Yunis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Infantile genetic agranulocytosis (IGA) has a high morbidity and mortality rate due to severe neutropenia. The pathogenetic mechanisms of this syndrome have not been elucidated. However, a recent clinical trial with recombinant human granulocyte-colony-stimulating factor (rhG-CSF) has shown a dramatic increase in the absolute neutrophil count in patients with IGA. This suggests that these patients have either a lack of granulocyte-colony-stimulating factor (G-CSF) or have a defect in the G-CSF receptors. A clinical trial of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in an infant with IGA is reported in this article. A marked eosinophilic response was observed without any increase in the absolute neutrophil count (ANC). In an effort to elucidate the pathogenetic mechanism underlying IGA, we examined (a) the in vitro response of patient's CFU-GM to rhGM-CSF and to rh-CSF and (b) the ability of patient's monocytes to produce G-CSF. Our results tend to support the thesis that the defect in IGA is at the G-CSF receptor level. We also found a lack of correlation between in vivo and in vitro response to rhGM-CSF.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalAmerican Journal of Pediatric Hematology/Oncology
Volume12
Issue number2
StatePublished - Jan 1 1990

Fingerprint

Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor Receptors
Neutrophils
Clinical Trials
Granulocyte-Macrophage Progenitor Cells
Neutropenia
Monocytes
Neutropenia, Severe Congenital, Autosomal Recessive 3
Morbidity
Mortality
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Daghistani, D., Jimenez, J. J., Toledano, S. R., Cirocco, R. E., & Yunis, A. A. (1990). Congenital neutropenia: A case study. American Journal of Pediatric Hematology/Oncology, 12(2), 210-214.

Congenital neutropenia : A case study. / Daghistani, D.; Jimenez, Joaquin J; Toledano, S. R.; Cirocco, R. E.; Yunis, Adel A.

In: American Journal of Pediatric Hematology/Oncology, Vol. 12, No. 2, 01.01.1990, p. 210-214.

Research output: Contribution to journalArticle

Daghistani, D, Jimenez, JJ, Toledano, SR, Cirocco, RE & Yunis, AA 1990, 'Congenital neutropenia: A case study', American Journal of Pediatric Hematology/Oncology, vol. 12, no. 2, pp. 210-214.
Daghistani D, Jimenez JJ, Toledano SR, Cirocco RE, Yunis AA. Congenital neutropenia: A case study. American Journal of Pediatric Hematology/Oncology. 1990 Jan 1;12(2):210-214.
Daghistani, D. ; Jimenez, Joaquin J ; Toledano, S. R. ; Cirocco, R. E. ; Yunis, Adel A. / Congenital neutropenia : A case study. In: American Journal of Pediatric Hematology/Oncology. 1990 ; Vol. 12, No. 2. pp. 210-214.
@article{07511d99476d4173b043f6b68c688862,
title = "Congenital neutropenia: A case study",
abstract = "Infantile genetic agranulocytosis (IGA) has a high morbidity and mortality rate due to severe neutropenia. The pathogenetic mechanisms of this syndrome have not been elucidated. However, a recent clinical trial with recombinant human granulocyte-colony-stimulating factor (rhG-CSF) has shown a dramatic increase in the absolute neutrophil count in patients with IGA. This suggests that these patients have either a lack of granulocyte-colony-stimulating factor (G-CSF) or have a defect in the G-CSF receptors. A clinical trial of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in an infant with IGA is reported in this article. A marked eosinophilic response was observed without any increase in the absolute neutrophil count (ANC). In an effort to elucidate the pathogenetic mechanism underlying IGA, we examined (a) the in vitro response of patient's CFU-GM to rhGM-CSF and to rh-CSF and (b) the ability of patient's monocytes to produce G-CSF. Our results tend to support the thesis that the defect in IGA is at the G-CSF receptor level. We also found a lack of correlation between in vivo and in vitro response to rhGM-CSF.",
author = "D. Daghistani and Jimenez, {Joaquin J} and Toledano, {S. R.} and Cirocco, {R. E.} and Yunis, {Adel A}",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "210--214",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Congenital neutropenia

T2 - A case study

AU - Daghistani, D.

AU - Jimenez, Joaquin J

AU - Toledano, S. R.

AU - Cirocco, R. E.

AU - Yunis, Adel A

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Infantile genetic agranulocytosis (IGA) has a high morbidity and mortality rate due to severe neutropenia. The pathogenetic mechanisms of this syndrome have not been elucidated. However, a recent clinical trial with recombinant human granulocyte-colony-stimulating factor (rhG-CSF) has shown a dramatic increase in the absolute neutrophil count in patients with IGA. This suggests that these patients have either a lack of granulocyte-colony-stimulating factor (G-CSF) or have a defect in the G-CSF receptors. A clinical trial of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in an infant with IGA is reported in this article. A marked eosinophilic response was observed without any increase in the absolute neutrophil count (ANC). In an effort to elucidate the pathogenetic mechanism underlying IGA, we examined (a) the in vitro response of patient's CFU-GM to rhGM-CSF and to rh-CSF and (b) the ability of patient's monocytes to produce G-CSF. Our results tend to support the thesis that the defect in IGA is at the G-CSF receptor level. We also found a lack of correlation between in vivo and in vitro response to rhGM-CSF.

AB - Infantile genetic agranulocytosis (IGA) has a high morbidity and mortality rate due to severe neutropenia. The pathogenetic mechanisms of this syndrome have not been elucidated. However, a recent clinical trial with recombinant human granulocyte-colony-stimulating factor (rhG-CSF) has shown a dramatic increase in the absolute neutrophil count in patients with IGA. This suggests that these patients have either a lack of granulocyte-colony-stimulating factor (G-CSF) or have a defect in the G-CSF receptors. A clinical trial of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in an infant with IGA is reported in this article. A marked eosinophilic response was observed without any increase in the absolute neutrophil count (ANC). In an effort to elucidate the pathogenetic mechanism underlying IGA, we examined (a) the in vitro response of patient's CFU-GM to rhGM-CSF and to rh-CSF and (b) the ability of patient's monocytes to produce G-CSF. Our results tend to support the thesis that the defect in IGA is at the G-CSF receptor level. We also found a lack of correlation between in vivo and in vitro response to rhGM-CSF.

UR - http://www.scopus.com/inward/record.url?scp=0025370264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025370264&partnerID=8YFLogxK

M3 - Article

C2 - 1696074

AN - SCOPUS:0025370264

VL - 12

SP - 210

EP - 214

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -